A Phase II Study of AMD3100 in Combination With Pembrolizumab in Head and Neck Squamous Cell Carcinoma Patients Who Have Progressed on Immune Checkpoint Blockade Therapy

Condition:   Head and Neck Cancer Interventions:   Drug: AMD3100;   Drug: Pembrolizumab Sponsors:   Massachusetts General Hospital;   Merck Sharp & Dohme Corp.;   AperiSys, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials